| Outcome Measures: |
Primary: The maximum plasma concentration (Cmax) of SHR3824, Cmax (a measure of the body's exposure to SHR3824) will be compared before and after coadministration with Simvastatin ., At protocol-specified times up to Day 7 and Day 8|The area under the plasma concentration-time curve (AUC) of SHR3824, AUC(a measure of the body's exposure to SHR3824) will be compared before and after coadministration with Simvastatin ., At protocol-specified times up to Day 7 and Day 8|The area under the plasma concentration-time curve (AUC) of Simvastatin and simavastatin acid ., AUC(a measure of the body's exposure to simvastatin and simavastatin acid) will be compared before and after coadministration with SHR3824 ., At protocol-specified times up to Day 1 and Day 8|The maximum plasma concentration (Cmax) of simvastatin and simavastatin acid., Cmax (a measure of the body's exposure to simvastatin and simavastatin acid) will be compared before and after coadministration with Simvastatin ., At protocol-specified times up to Day 1 and Day 8|The number of volunteers with adverse events as a measure of safety and tolerability., up to day 15 |
|
